Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-017314
Filing Date
2025-06-13
Accepted
2025-06-13 19:30:17
Documents
1
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 form4-06132025_070609.html 4  
1 form4-06132025_070609.xml 4 6104
  Complete submission text file 0001415889-25-017314.txt   7562
Mailing Address 10835 ROAD TO THE CURE SUITE 205 SAN DIEGO CA 92121
Business Address
Gujrathi Sheila (Reporting) CIK: 0001575202 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40475 | Film No.: 251048104

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Issuer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)